A single course of low-dose radiation therapy may provide a safe and effective alternative treatment option for people with painful knee osteoarthritis according to a new randomized, placebo-controlled clinical trial. The study showed patients with mild to moderate knee osteoarthritis reported significant reductions in pain and improved physical function in the four months after receiving the low dose of radiation, which was just a small fraction of what’s used to treat cancer. Results will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

University of Cincinnati Cancer Center researchers will present abstracts at the American Society for Radiation Oncology (ASTRO) annual meeting Sept. 27 through Oct. 1 in San Francisco.

Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share the latest research and clinical trial results at the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting.

Genetic testing can identify patients with HPV-positive throat cancer who may benefit from lower radiation doses, according to Cleveland Clinic research. The study, published in the Journal of Clinical Investigation, builds on a growing body of evidence that radiation treatment can be personalized using tumor genomics, potentially shifting treatment approaches from the norm, where radiation is prescribed at a uniform dose, to one called Genomic Adjusted Radiation Dose (GARD), where radiation is prescribed to a desired effect. 

The discovery, published in Cell Reports, positions IGF2BP3 as a “master switch” in leukemia, linking metabolism and RNA regulation, processes long thought to operate independently. 

Researchers at Fox Chase Cancer Center were part of an international team that found a steep rise in kidney cancer cases will be driven largely by preventable risk factors such as obesity, smoking, lack of exercise, diabetes, and hypertension.

The University of Cincinnati Cancer Center’s Ahmet Kaynak examined the unique tumor microenvironment of pancreatic ductal adenocarcinoma cells, identified one of the key proteins that aids tumor treatment resistance and developed a new drug targeting this protein that reduced tumor size and increased survival in animal models.